CSF3 and metastatic malignant neoplasm: Failure to administer G-CSF prophylaxis could be especially detrimental in patients with metastatic cancer, who are often older and have more complex comorbidity profiles (vs. non-metastatic patients) and thus for whom the risk of FN may be elevated and the consequences of FN may be more severe [19–21].